Price
CHART BY
Frequently asked questions
What is AC Immune's market capitalization?
The market capitalization of AC Immune is CHF 326.69M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for AC Immune?
AC Immune's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.84. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for AC Immune's stock?
Currently, 4 analysts cover AC Immune's stock, with a consensus target price of CHF 7.105. Analyst ratings provide insights into the stock's expected performance.
What is AC Immune's revenue over the trailing twelve months?
Over the trailing twelve months, AC Immune reported a revenue of CHF 4.28M.
What is the EBITDA for AC Immune?
AC Immune's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -CHF 79.74M. EBITDA measures the company's overall financial performance.
What is the free cash flow of AC Immune?
AC Immune has a free cash flow of -CHF 87.79M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does AC Immune have, and what sector and industry does it belong to?
AC Immune employs approximately 122 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of AC Immune's shares?
The free float of AC Immune is 62.52M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- CHF 326.69M
- EPS (TTM)
- -$0.84
- Free Float
- 62.52M
- Revenue (TTM)
- CHF 4.28M
- EBITDA (TTM)
- -CHF 79.74M
- Free Cashflow (TTM)
- -CHF 87.79M
Pricing
- 1D span
- $3.141$3.259
- 52W span
- $1.46$4.00
Analyst Ratings
The price target is CHF 7.105 and the stock is covered by 4 analysts.
Buy
4
Hold
0
Sell
0
Information
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
- Employees
- 122
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- CH0329023102
- Primary Ticker
- ACIU
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet